How PT-141 works, what the trials measured, and exactly who it is approved for

In plain English

This page covers how PT-141 works and what the studies found. The one-paragraph version: PT-141 (the research name for bremelanotide) acts on switches in the brain — melanocortin MC4R/MC3R receptors — that influence sexual desire, rather than on the blood vessels the way erectile pills do. In large trials it raised desire and lowered desire-related distress in premenopausal women with low desire, by a real but small amount. It is FDA-approved for that group only. Everything below adds the detail, with each number tied to the study it came from.

How does PT-141 work?

By agonizing melanocortin MC4R (and secondarily MC3R) receptors in hypothalamic circuits — the medial preoptic area among them — and engaging dopamine signaling linked to sexual desire ^[1][2]. It is a central mechanism, not a vascular one. Systemic dosing produced erections in rats and nonhuman primates and activated hypothalamic neurons (a marker called c-Fos rose), and produced rapid, dose-dependent erectile activity in men with erectile dysfunction in early work ^[1]. The site of action is the nervous system; the readout is desire and arousal, not blood flow.

The receptors themselves are part of a family of five (MC1R through MC5R) that respond to melanocortin peptides such as alpha-MSH. PT-141 is selective for the central MC3R/MC4R subtypes, which is why its effects center on desire and appetite rather than on pigment or adrenal function. The fuller picture sits in the cards below.

What receptors does PT-141 act on?

Chiefly the melanocortin 4 receptor (MC4R) and, secondarily, the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system ^[1]. MC4R in hypothalamic desire circuits is the principal target; the same receptor sits in appetite circuits, which is why caloric-intake and weight effects appear at high-frequency dosing ^[6]. A 2025 female-Syrian-hamster study found MC3R/MC4R mRNA concentrated in ventral-tegmental-area dopamine neurons, but reported that bremelanotide did not change melanocortin-receptor mRNA there and did not enhance sexual reward in a place-preference test — a careful, partly negative result suggesting the molecule does not act on that particular reward circuit ^[12].

What the research describes as PT-141's benefits

The benefit, as the trials measured it, is an increase in sexual desire and a reduction in the distress that low desire causes — in the approved population, and to a modest degree. In the integrated RECONNECT Phase 3 data, bremelanotide 1.75 mg subcutaneous as-needed produced an FSFI-desire change of +0.35 (P<.001) and an FSDS-DAO item-13 change of -0.33 (P<.001) versus placebo across 24 weeks ^[3]. Both coprimary endpoints were met in both identical trials.

The honest reading is that these effects are statistically real and clinically small, and independent re-analyses have argued exactly that — questioning the clinical meaningfulness of changes of this size and the choice of outcome measures. A 2025 conference abstract reported positive effects on female sexual arousal and orgasm beyond the desire endpoints ^[14], and a separate 2025 abstract set bremelanotide beside flibanserin (the other approved HSDD medication) and testosterone therapy in a comparative analysis ^[15]. Conference abstracts sit a tier below peer-reviewed full text, and we flag them as such. The benefit is not a guaranteed outcome for any individual; it is a group-level, trial-measured signal.

What is a melanocortin receptor agonist?

A molecule that switches on one or more of the five melanocortin receptors (MC1R-MC5R). PT-141 targets the central MC3R/MC4R subtypes, which influence sexual desire and appetite ^[1]. A class review situated bremelanotide within this melanocortin family as a treatment approach for male and female sexual dysfunction ^[8], and the receptor pharmacology is what makes the molecule's effects both central and, at MC1R, pigment-related on repeated dosing.

The RECONNECT Phase 3 trials and the long-term extension

The approval rests on the RECONNECT Phase 3 trials — two identical randomized, double-blind, placebo-controlled studies (studies 301 and 302), 1,267 premenopausal women with HSDD, bremelanotide 1.75 mg subcutaneous as-needed over 24 weeks ^[3]. The coprimary desire and distress endpoints were met in both. The most common adverse events were nausea, flushing, and headache ^[3].

The record did not stop at 24 weeks. A 52-week open-label extension enrolled 684 women, found no new safety signals, and saw the desire improvements sustained ^[4]. That extension is also where the tolerability picture sharpened: the most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[4]. Nausea was the principal tolerability issue and a notable reason participants stopped — a fact we carry forward, in full, on the PT-141 side effects page.

Mechanistic brain imaging: MC4R and the desire circuit

The clearest mechanistic human evidence comes from functional MRI. In a randomized, double-blind, placebo-controlled crossover study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli — enhancing amygdala-insula functional connectivity and cerebellar and supplementary-motor activity ^[5]. This is direct evidence that the molecule modulates central sexual processing, consistent with the receptor pharmacology and distinct from any peripheral blood-flow account.

Is PT-141 FDA-approved, and for whom?

Yes — narrowly. Bremelanotide injection received FDA approval in June 2019 (NDA 210557) for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and for no other indication ^[6][11]. The approved regimen is 1.75 mg subcutaneously, as needed ^[6]. Men, postmenopausal women, and sexual-performance use are off-label — not supported by the approval. The FDA approval status is the single most misstated fact about PT-141, so we state it precisely: one molecule, one approved indication, one approved population. The male and erectile evidence is early-phase and investigational; the PT-141 for men page reads it on those terms.